Recursion Pharmaceuticals, Inc. (RXRX)
3.835
-0.18
(-4.36%)
USD |
NASDAQ |
Oct 13, 16:00
3.90
+0.06
(+1.69%)
After-Hours: 04:34
Recursion Pharmaceuticals Free Cash Flow : -354.26M for June 30, 2026
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| June 30, 2026 | -354.26M |
| March 31, 2026 | -328.08M |
| December 31, 2025 | -380.44M |
| September 30, 2025 | -450.20M |
| June 30, 2025 | -396.38M |
| March 31, 2025 | -401.06M |
| December 31, 2024 | -376.22M |
| September 30, 2024 | -335.64M |
| June 30, 2024 | -345.60M |
| March 31, 2024 | -330.63M |
| December 31, 2023 | -300.33M |
| September 30, 2023 | -276.56M |
| Date | Value |
|---|---|
| June 30, 2023 | -265.92M |
| March 31, 2023 | -272.58M |
| December 31, 2022 | -120.88M |
| September 30, 2022 | -133.78M |
| June 30, 2022 | -113.43M |
| March 31, 2022 | -75.20M |
| December 31, 2021 | -198.41M |
| September 30, 2021 | -128.81M |
| June 30, 2021 | -106.34M |
| March 31, 2021 | -83.80M |
| December 31, 2020 | -52.13M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| Absci Corp. | -108.97M |
| Twist Bioscience Corp. | -93.22M |
| Editas Medicine, Inc. | -120.55M |
| Amgen, Inc. | 10.18B |
| Halozyme Therapeutics, Inc. | 806.22M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -105.95M |
| Cash from Investing (Quarterly) | -1.959M |
| Cash from Financing (Quarterly) | -1.267M |
| Free Cash Flow Per Share (Quarterly) | -0.2027 |
| Free Cash Flow to Equity (Quarterly) | -102.17M |
| Free Cash Flow to Firm (Quarterly) | -107.60M |
| Free Cash Flow Yield | -18.15% |